Identifying a variety of patients

eligible for iStent infinite®

iStent infinite® gives you the versatility to treat a variety of patients who have failed prior medical and surgical intervention, when combined with cataract surgery or in a **standalone surgical setting.**

Failed medical

- Uncontrolled on medication
- Non-compliant and non-adherent to treatment
- Allergic to glaucoma medication
- Intolerant to glaucoma medication due to sequelae
- Burdened with underlying ocular surface disease
- Experiencing decreased quality of life

Treatment Non-Adherence

Hyperemia

Periorbital Fat Atrophy

Failed surgical

- Failed filtering surgery
- Failed cilioablative surgery
- Other failed surgical intervention (upon surgeon discretion)



Failed Tube Shunt

Failed Bleb

Consider earlier intervention with iStent infinite® in place of more invasive procedures.

REAL-WORLD PATIENT PROFILES

iStent infinite® is the only trabecular micro-bypass approved for standalone intervention. See just how versatile iStent infinite® can be for a variety of patients who have failed prior medical and surgical intervention.

Example Patient 1

Female, age 66

Medications (failed): 2
Prior Surgery (failed): Yes
Sequelae: Yes

Notes:
Patient was unsuccessful with trabeculectomy and ECP

Example Patient 2



Male, age 49

Medications (failed): 3
Prior Surgery (failed): Yes
Sequelae: Yes

Notes:
Patient is non-compliant with prescribed drops and ECP was unsuccessful

Example Patient 3

Male, age 78

Medications (failed): 0
Prior Surgery (failed): Yes
Sequelae: No

Notes:
Patient was diagnosed over 3 years ago, is allergic to glaucoma drops, and was unsuccessful with SLT

ECP=endoscopic cyclophotocoagulation; SLT=selective laser trabeculoplasty.

Ordering Information:

Order #: iS3-US
800-GLAUKOS (452-8567)
Fax: 949-367-9838
CustomerService@glaukos.com

iStent infinite® IMPORTANT SAFETY INFORMATION

INDICATION FOR USE. The iStent infinite® Trabecular Micro-Bypass System Model iS3 is an implantable device intended to reduce the intraocular pressure (IOP) of the eye. It is indicated for use in adult patients with primary open-angle glaucoma in whom previous medical and surgical treatment has failed. **CONTRAINDICATIONS.** The iStent infinite is contraindicated in eyes with angle-closure glaucoma where the angle has not been surgically opened, acute traumatic, malignant, active uveitic, or active neovascular glaucoma, discernible congenital anomalies of the anterior chamber (AC) angle, retrobulbar tumor, thyroid eye disease, or Sturge-Weber Syndrome or any other type of condition that may cause elevated episcleral venous pressure. **WARNINGS.** Gonioscopy should be performed prior to surgery to exclude congenital anomalies of the angle, PAS, rubeosis, or conditions that would prohibit adequate visualization that could lead to improper placement of the stent and pose a hazard. **MRI INFORMATION.** The iStent infinite is MR-Conditional, i.e., the device is safe for use in a specified MR environment under specified conditions; please see Directions for Use (DFU) label for details. **PRECAUTIONS.** The surgeon should monitor the patient postoperatively for proper maintenance of IOP. Three out of 61 participants (4.9%) in the pivotal clinical trial were phakic. Therefore, there is insufficient evidence to determine whether the clinical performance of the device may be different in those who are phakic versus in those who are pseudophakic. **ADVERSE EVENTS.** The most common postoperative adverse events reported in the iStent infinite pivotal trial included IOP increase ≥ 10 mmHg vs. baseline IOP (8.2%), loss of BSCVA ≥ 2 lines (11.5%), ocular surface disease (11.5%), perioperative inflammation (6.6%) and visual field loss ≥ 2.5 dB (6.6%). **CAUTION**: Federal law restricts this device to sale by, or on the order of, a physician. Please see DFU for a complete list of contraindications, warnings, precautions, and adverse events.

PM-US-0955

GLAUKOS